Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron

Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). We are currently evaluating vibegron in a pivotal Phase 3 international clinical trial for the treatment of OAB. We also plan to commence a Phase 3 clinical trial for OAB in men with BPH and a Phase 2a clinical trial for IBS-associated pain by the end of 2018.

LEARN MORE

women-sleeping

Latest News

The latest posts and articles

Urovant Sciences Licenses Novel Gene…

There are no currently available FDA-approved gene therapy treatments for overactive bladder Urovant expects to…

Urovant Sciences Appoints Sef Kurstjens…

BASEL, Switzerland and IRVINE, Calif., July [9], 2018 /PRNewswire/ — Urovant Sciences, a clinical-stage biopharmaceutical…

Urovant Sciences Strengthens Executive Management…

Cornelia Haag-Molkenteller, former VP and Therapeutic Area Head, Clinical Development, for Urology, Women’s Health, and…

Copyright 2018 © All Rights Reserved